Drugs / Doxorubicin Hydrochloride [HCl]
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05283720 | Jun 2022 → Nov 2032 expected | non-Hodgkin lymphoma | Genmab | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxorubicin Hydrochloride [HCl] | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05283720 ↗ |
| Route | Intravenous | “IV; Injection” NCT05283720 ↗ |